Myo-inositol Stress Meta-analysis: What the Evidence Says

Quick Answer

Myo-inositol Stress Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Subclinical hypothyroidism has been associated with metabolic disturbances, increased cardiovascular risk, and reduced quality of life, highlighting the need for effective management strategies. [Stanchev Pavel (2026); evidence level 1]
• It is thought to enhance TSH signaling and support thyroid hormone synthesis, with emerging clinical evidence suggesting a beneficial effect on thyroid function parameters. [Stanchev Pavel (2026); evidence level 1]
• Anxiety and depressive disorders frequently co-occur, and converging evidence from symptom profiles, longitudinal course, shared neurobiological markers, familial aggregation, and treatment response supports a substantial overlap between these conditions. [Derkaczew Maria (2026); evidence level 4]
• Importantly, even agents considered comparatively "benign", such as non-benzodiazepine anxiolytics, may rarely cause significant neurological adverse effects in vulnerable individuals, as illustrated by reports of buspirone-associated dyskinesia or dystonia, plausibly related to its interactions with dopaminergic signaling. [Derkaczew Maria (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For myo-inositol stress meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Stanchev Pavel (2026). Myo-Inositol Plus Selenium vs. Selenium Alone in Hashimoto’s Thyroiditis with Subclinical Hypothyroidism: A Systematic Review and Updated Meta-Analysis with Trial Sequential Analysis. DOI: 10.3390/jcm15093179. PMCID: PMC13164135. PMID: 42122912. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13164135/
• Derkaczew Maria (2026). Potential Anxiolytic Effects of Selected Inositol Stereoisomers—A Narrative Review. DOI: 10.3390/cells15110970. PMCID: PMC13256961. PMID: 42274562. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13256961/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.